459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREG
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797632777489743872 |
|---|---|
| author | Dirk Schadendorf Carola Berking Lisa Zimmer Ralf Gutzmer Alexander Kreuter Andrea Forschner Elisabeth Livingstone Bastian Schilling Selma Ugurel Peter Mohr Jessica Hassel Patrick Terheyden Henner Stege Katharina Kaehler Sebastian Haferkamp Friedegund Meier Claudia Pfoehler Dirk Debus Rudolf Herbst Carmen Loquai Frank Meiss Martin Kaatz Jens Ulrich Edgar Dippel Michael Weichenthal Ulrike Leiter Markus V Heppt Michael Sachse Fabian Ziller Stephan Grabbe Georg Lodde Maximilian Haist Friederike Rogall Yuqi Tan Kai Christian Klespe Michael Tronnier Imke von Wasielewski Felix Kieker Christopher Gebhardt Jan Simon |
| author_facet | Dirk Schadendorf Carola Berking Lisa Zimmer Ralf Gutzmer Alexander Kreuter Andrea Forschner Elisabeth Livingstone Bastian Schilling Selma Ugurel Peter Mohr Jessica Hassel Patrick Terheyden Henner Stege Katharina Kaehler Sebastian Haferkamp Friedegund Meier Claudia Pfoehler Dirk Debus Rudolf Herbst Carmen Loquai Frank Meiss Martin Kaatz Jens Ulrich Edgar Dippel Michael Weichenthal Ulrike Leiter Markus V Heppt Michael Sachse Fabian Ziller Stephan Grabbe Georg Lodde Maximilian Haist Friederike Rogall Yuqi Tan Kai Christian Klespe Michael Tronnier Imke von Wasielewski Felix Kieker Christopher Gebhardt Jan Simon |
| author_sort | Dirk Schadendorf |
| collection | DOAJ |
| first_indexed | 2024-03-11T11:41:35Z |
| format | Article |
| id | doaj.art-85987b665cf74916884422bf2059f401 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T11:41:35Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-85987b665cf74916884422bf2059f4012023-11-10T02:20:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0459459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREGDirk Schadendorf0Carola Berking1Lisa Zimmer2Ralf Gutzmer3Alexander Kreuter4Andrea Forschner5Elisabeth Livingstone6Bastian Schilling7Selma Ugurel8Peter Mohr9Jessica Hassel10Patrick Terheyden11Henner Stege12Katharina Kaehler13Sebastian Haferkamp14Friedegund Meier15Claudia Pfoehler16Dirk Debus17Rudolf Herbst18Carmen Loquai19Frank Meiss20Martin Kaatz21Jens Ulrich22Edgar Dippel23Michael Weichenthal24Ulrike Leiter25Markus V Heppt26Michael Sachse27Fabian Ziller28Stephan Grabbe29Georg Lodde30Maximilian Haist31Friederike Rogall32Yuqi Tan33Kai Christian Klespe34Michael Tronnier35Imke von Wasielewski36Felix Kieker37Christopher Gebhardt38Jan Simon397West German Cancer Center, University Hospital Essen, Essen, GermanyComprehensive Cancer Center, Uniklinikum Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, GermanyDepartment of Dermatology, Venerology and Allergology, University Hospital Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, GermanyDepartment of Dermatology, Muelenkreiskliniken Minden and Ruhr University Bochum, Minden, GermanyDepartment of Dermatology, Venerology and Allergology, Helios St. Elisabeth Klinik Oberhausen, University Witten-Herdecke, Oberhausen, GermanyCenter for Dermatooncology, Department of Dermatology, Eberhard-Karls University of Tübingen, Tubingen, GermanyDepartment of Dermatology, University of Duisburg-Essen, Essen, GermanyDepartment of Dermatology, University Hospital Würzburg, Würzburg, GermanyDepartment of Dermatology, Venerology and Allergology, University Hospital Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, GermanyDepartment of Dermatology, Elbe Kliniken Buxtehude, Buxtehude, Germany20Interdisziplinäre Tumorambulanz Nationals Centrium Für Tumorerkrankungen, Heidelberg, GermanyDepartment of Dermatology, Allergology and Venerology, University Medical Center Schleswig Holstein Lübeck Campus, Lubeck, GermanyDepartment of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, GermanySkin Cancer Center, Department of Dermatology, University Hospital Kiel, Kiel, GermanyDepartment of Dermatology, University Hospital Regensburg, Regensburg, GermanyDepartment of Dermatology, University Hospital Carl Gustav Carus, Dresden, GermanyDepartment of Dermatology, Saarland University Hospital and Saarland University Faculty of Medicine, Homburg, GermanyDepartment of Dermatology, Nuremberg Hospital, Nurnberg, GermanyDepartment of Dermatology, HELIOS Hospital Erfurt, Erfurt, GermanyDepartment of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, GermanyDepartment of Dermatology and Venerology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, GermanyDepartment of Dermatology, DRK Hospital Chemnitz-Rabenstein, Rabenstein, GermanyDepartment of Dermatology and Allergy, Harzklinikum Dorothea Christiane Erxleben GmbH, Quedlinburg, GermanyDepartment of Dermatology, Ludwigshafen City Hospital, Ludwigshafen, GermanyDepartment of Dermatology, Skin Cancer Center, University Hospital Schleswig-Holstein - Campus Kiel, Kiel, GermanyCenter for Dermatooncology, Department of Dermatology, Eberhard-Karls University of Tübingen, Tubingen, GermanyDepartment of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, GermanyDepartment of Dermatology, Hospital Bremerhaven Reinkenheide, Bremerhaven, Germany19DRK Hospital Chemnitz-Rabenstein, Chemnitz-Rabenstein, Saxony, GermanyDepartment of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, GermanyDepartment of Dermatology, Venerology and Allergology, University Hospital Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, GermanyDepartment of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany2University Medical Center Mainz, Mainz, Rhineland-Palatinate, GermanyDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USASkin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover, GermanyDepartment of Dermatology, HELIOS Hospital Hildesheim, Hildesheim, Germany3Hannover Medical School, Hannover, Lower saxony, Germany26Vivantes Klinikum Neukölln, Berlin, Berlin, Germany28University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Hamburg, Germany29University Hospital Leipzig, Leipzig, Saxony, Germany |
| spellingShingle | Dirk Schadendorf Carola Berking Lisa Zimmer Ralf Gutzmer Alexander Kreuter Andrea Forschner Elisabeth Livingstone Bastian Schilling Selma Ugurel Peter Mohr Jessica Hassel Patrick Terheyden Henner Stege Katharina Kaehler Sebastian Haferkamp Friedegund Meier Claudia Pfoehler Dirk Debus Rudolf Herbst Carmen Loquai Frank Meiss Martin Kaatz Jens Ulrich Edgar Dippel Michael Weichenthal Ulrike Leiter Markus V Heppt Michael Sachse Fabian Ziller Stephan Grabbe Georg Lodde Maximilian Haist Friederike Rogall Yuqi Tan Kai Christian Klespe Michael Tronnier Imke von Wasielewski Felix Kieker Christopher Gebhardt Jan Simon 459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREG Journal for ImmunoTherapy of Cancer |
| title | 459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREG |
| title_full | 459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREG |
| title_fullStr | 459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREG |
| title_full_unstemmed | 459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREG |
| title_short | 459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREG |
| title_sort | 459 treatment management of braf mutant melanoma patients following tumor recurrence upon adjuvant therapy a multicenter real world cohort study from the prospective skin cancer registry adoreg |
| work_keys_str_mv | AT dirkschadendorf 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT carolaberking 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT lisazimmer 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT ralfgutzmer 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT alexanderkreuter 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT andreaforschner 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT elisabethlivingstone 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT bastianschilling 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT selmaugurel 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT petermohr 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT jessicahassel 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT patrickterheyden 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT hennerstege 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT katharinakaehler 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT sebastianhaferkamp 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT friedegundmeier 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT claudiapfoehler 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT dirkdebus 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT rudolfherbst 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT carmenloquai 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT frankmeiss 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT martinkaatz 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT jensulrich 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT edgardippel 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT michaelweichenthal 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT ulrikeleiter 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT markusvheppt 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT michaelsachse 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT fabianziller 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT stephangrabbe 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT georglodde 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT maximilianhaist 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT friederikerogall 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT yuqitan 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT kaichristianklespe 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT michaeltronnier 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT imkevonwasielewski 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT felixkieker 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT christophergebhardt 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg AT jansimon 459treatmentmanagementofbrafmutantmelanomapatientsfollowingtumorrecurrenceuponadjuvanttherapyamulticenterrealworldcohortstudyfromtheprospectiveskincancerregistryadoreg |